The cellular mechanisms and regulation of metastasis formation

Molecular Biology

Volumn 48, Issue 2, 2014, Pages 165-180

  Chikina, A S ^a   Alexandrova, A Yu ^a  

^a N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

cancer stem cells; cell migration; hypoxia; mesenchymal to amoeboid transition; metastatic cell population; premetastatic niche

Indexed keywords

EID: 84899692931     PISSN: 00268933     EISSN: 16083245     Source Type: Journal    
DOI: 10.1134/S0026893314020046     Document Type: Review

References (72)

1. Perelmuter V. M., Manskikh V. N. 2012. Preniche as missing link of the metastatic niche concept explaining organ-preferential metastasis of malignant tumors and the type of metastatic disease. Biochemistry (Moscow). 77(1), 111-118.
2. Wolf K., Muller R., Borgmann S., Brocker E., Friedl P. 2003. Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases. Blood. 102, 3262-3269.
3. Ridley A. 2011. Life at the leading edge. Cell. 145, 1012-1022.
4. Friedl P., Wolf K. 2010. Plasticity of cell migration: A multiscale tuning model. Cell Biol. 188, 11-19.
5. Fackler O., Grosse R. 2008. Cell motility through plasma membrane blebbing. J. Cell Biol. 181(6), 879-884.
6. Cougoule C., Goethem E., Le Cabec V., Lafouresse F. 2012. Blood leukocytes and macrophages of various phenotypes have distinct abilities to form podosomes and to migrate in 3D environments. Eur. J. Cell Biol. 91, 938-949.
7. Svitkina T., Borisy G. 1999. Arp2/3 complex and actin depolymerizing factor/cofilin in dendritic organization and treadmilling of actin filament array in lamellipodia. Cell Biol. 31, 1009-1026.
8. Pollard T., Borisy G. 2003. Cellular motility driven by assembly and disassembly of actin filaments. Cell. 112(4), 453-465.
9. Friedl P., Wolf K. 2003. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nature Rev. Cancer. 3, 362-374.
10. Madsen C., Sahai E. 2010. Cancer dissemination: Lessons from leukocytes. Cell. 9(1), 13-26.
11. Charras G., Paluch E. 2008. Blebs lead the way: How to migrate without lamellipodia. Nature. 9(9), 730-736.
12. Nürnberg A., Kitzing T., Grosse R. 2011. Nucleating actin for invasion. Nature Rev. Cancer. 1(3), 177-187.
13. Otto A., Collins-Hooper H., Patel A., Dash P., Patel K. 2011. Adult skeletal muscle stem cell migration is mediated by a blebbing/amoeboid mechanism. Rejuvenat. Res. 14(3), 249-260.
14. Yoshida K., Soldati T. 2006. Dissection of amoeboid movement into two mechanically distinct modes. J. Cell Sci. 119, 3833-3844.
15. Smith L., Aranda-Espinoza H., Haun J., Dembo M., Hammer D. 2007. Neutrophil traction stresses are concentrated in the uropod during migration. Biophys. J. 92, L58-L60.
16. Vignjevic D., Schoumacher M., Gavert N., Janssen K., Jih G., Louvard D., Ben-Zeev A., Robine S. 2007. Fascin, a novel target of b-catenin-tcf signaling, is expressed at the invasive front of human colon cancer. Cancer Res. 67, 6844-6853.
17. Chan A., Coniglio S., Chuang Y., Michaelson D., Knaus U., Philips M., Symons M. 2005. Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion. Oncogene. 24, 7821-7829.
18. Bergerta M., Chandradossa S., Desaia R., Palucha E. 2012. Cell mechanics control rapid transitions between blebs and lamellipodia during migration. Proc. Natl. Acad. Sci. U. S. A. 109(36), 14434-14439.
19. Pankova K., Rosel A., Novotny A., Brabek J. 2009. The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. Cell. Mol. Life Sci. 67(1), 63-71.
20. Bergert M., Chandradoss S., Desai R., Paluch E. 2012. Cell mechanics control rapid transitions between blebs and lamellipodia during migration. Proc. Natl. Acad. Sci. U. S. A. 109(36), 14434-14439.
21. Gadea G., Toledo M., Anguille C., Roux P. 2007. Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices. J. Cell Biol. 178, 23-30.
22. Muller P., Caswell P., Doyle B., Iwanicki M., Tan E., Karim S., Lukashchuk N., Gillespie D., Ludwig R., Gosselin P. 2009. Mutant p53 drives invasion by promoting integrin recycling. Cell. 139, 1327-1341.
23. Nakamura T., Teramoto H., Ichihara A. 1986. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary culture. Proc. Natl. Acad. Sci. U. S. A. 86, 6489-6493.
24. Zarnegar R., Michalopoulo M. 1989. Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Res. 49, 3314-3320.
25. Stoker M., Perriman M. 1985. An epithelial scatter factor released by embryo fibroblasts. J. Cell. Sci. 77, 209-223.
26. Stoker M., Gherardi E., Perryman M., Gray J. 1987. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 327, 239-242.
27. Gumbiner B. 1992. Epithelial morphogenesis. Cell. 69, 385-387.
28. Prat M., Narsimhan R., Crepaldi T., Nicotra M., Natali P., Gomogio P. 1991. The receptor encoded by the human c-met oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int. J. Cancer. 49, 323-328.
29. Razban V., Sahebqadam Lotfi A., Soleimani M., Ahmadi H., Massumi M., Khajeh S., Ghaedi M., Arjmand S., Najavand S., Khoshdel A. 2012. HIF-1a over-expression induces angiogenesis in mesenchymal stem cells. BioResearch. 1(4), 174-183.
30. Razmkhah M., Jaberipour M., Safaei A., Talei A., Erfani N., Ghaderi A. 2012. Chemokine and chemokine receptors: A comparative study between metastatic and nonmetastatic lymph nodes in breast cancer patients. Eur. Cytokine Netw. 23(3), 72-77.
31. Ogunwobi O., Puszyk W., Dong H., Liu C. 2013. Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma. PLoS ONE. 8(5), e63765.
32. Zou Y., Kottmann A., Kuroda M., Taniuchi I., Littman D. 1998. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 93(6685), 595-599.
33. Albert S., Riveiro M., Halimi C., Hourseau M., Couvelard A., Serova M., Barry B., Raymond E., Faivre S. 2013. Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma. Head Neck. doi 10. 1002/hed. 23217.
34. Pal'tsev M. A. 2009. Biologiya stvolovykh kletok i kletochnye tekhnologii (Stem Cell Biology and Cell Technologies). Moscow: Meditsina.
35. Hannelien V., Karel G., Damme V., Sofie S. 2012. The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. Biochim. Biophys. Acta. 1825, 117-129.
36. Otani Y., Kijima T., Kohmo S., Oishi S., Minami T., Nagatomo I., Takahashi R., Hirata H., Suzuki M. 2012. Suppression of metastases of small cell lung cancer cells in mice by a peptidic CXCR4 inhibitor TF14016. FEBS Lett. 586, 3639-3644.
37. Heazlewood S., Neaves R., Williams B., Haylock D., Adams T., Nilsson S. 2013. Megakaryocytes co-localize with hemopoietic stem cells and release cytokines that up-regulate stem cell proliferation. Stem Cell Res. 11(2), 782-792.
38. Li L., Neaves W. 2006. Normal stem cells and cancer stem cells: The niche matters. Cancer Res. 66, 4553-4557.
39. Reuter S., Gupta S., Chaturvedi M., Aggarwal B. 2010. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic. Biol. Med. 49(11), 1603-1616.
40. Chaffer C., Brueckmann I., Scheel C., Kaestlia A., Wiggins P., Rodriguesa L., Brooksa M., Reinhardt F., Polyakc Y., Arendt L., Kuperwasser C., Bierie B., Weinberg R. 2011. Normal and neoplastic non stem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. U. S. A. 108(19), 7950-7955.
41. Carina V., Zito G., Pizzolanti G., Richiusa P., Criscimanna A., Rodolico V., Tomasello L., Pitrone M., Arancio W., Giordano C. 2013. Multiple pluripotent stem cell markers in human anaplastic thyroid cancer: The putative upstream role of SOX2. Thyroid. 23(7), 829-837.
42. Mimeault M., Batra S. 2013. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J. Cell Mol. Med. 17(1), 30-54.
43. Borrull A., Ghislin S., Deshayes F., Lauriol J., AlcaideLoridan C., Middendorp S. 2012. Nanog and Oct4 overexpression increases motility and transmigration of melanoma cells. J. Cancer Res. Clin. Oncol. 138, 1145-1154.
44. Chiou S., Wang M., Chou Y., Chen C., Hong C., Hsieh W. 2010. Coexpression of oct4 and nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 70(24), 10433-10444.
45. Ben-Porath I., Thomson M., Carey V., Ge R., Bell G., Regev A. 2008. An embryonic stem cell like gene expression signature in poorly differentiated aggressive human tumors. Nature Genet. 40(5), 499-507.
46. Duda D., Jain R. 2010. Pre-metastatic lung "niche": Is VEGFR1 activation required? Cancer Res. 70(14), 5670-5673.
47. Bustelo X. 2012. Intratumoral stages of metastatic cells: A synthesis of ontogeny, Rho/RacGTPases, epithelialmesenchymal transitions, and more. Bioessays. 34, 748-759.
48. Greenbaum A., Hsu Y., Day R., Schuettpelz L., Christopher M., Borgerding J., Nagasawa T., Link D. 2013. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature. 495(7440), 227-230.
49. Kulbe H., Levinson N., Balkwill F., Wilsoni J. 2004. The chemokine network in cancer: Much more than directing cell movement. Int. J. Dev. Biol. 48, 489-496.
50. Li Y., Laterra J. 2012. Cancer stem cells: Distinct entities or dynamically regulated phenotypes? Cancer Res. 72(3), 576-580.
51. Talmadge J. 2007. Clonal selection of metastasis within the life history of a tumor. Cancer Res. 67, 11471-11475.
52. Borovski T., Sousa F., Melo E., Vermeulen L. 2011. Cancer stem cell niche: The place to be. Cancer Res. 71(3), 634-639.
53. Okajama M., Kokura S., Ishikawa T., Mizushima K., Tsuchiya R., Matsuyama T., Adachi S., Okajama T., Sakamoto N. 2013. Anoxia/reoxygenation induces epithelial-mesenchymal transition in human colon cancer cell lines. Oncol. Rep. 29, 2311-2317.
54. Rofstad E., Galappathi K., Mathiesen B. 2007. Fluctuating and diffusion-limited hypoxia in hypoxiainduced metastasis. Clin. Cancer Res. 13, 1971-1978.
55. Finger E., Giaccia A. 2010. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metast. Rev. 29, 285-293.
56. Marignol L., Rivera-Figueroa K., Lynch T., Hollywood D. 2013. Hypoxia, notch signalling, and prostate cancer. Nature Rev. Urol. 10(7), 405-413.
57. Arvidsson Y., Bergstrom A., Arvidsson L., Kristiansson E., Ahlman H., Nilsson O. 2010. Hypoxia stimulates CXCR4 signalling in ileal carcinoids. Endocr. Relat. Cancer. 17(2), 303-316.
58. Holmes K., Roberts O., Thomas A., Cross M. 2007. Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cell. Signalling. 19, 2003-2012.
59. Kaplan R., Rafii S., Lyden D. 2006. Preparing the "soil": The premetastatic niche. Cancer Res. 66, 11089-11093.
60. Munnink O., Tamas K., Hooge M., Vedelaar S., Timmer-Bosscha H. 2013. Placental growth factor (PlGF): Specific uptake in tumor microenvironment of 89Zrlabeled PlGF antibody RO5323441. J. Nucl. Med. 54, 929-935.
61. Fazilaty H., Gardaneh M., Bahrami T., Salmaninejad A., Behnam B. 2013. Crosstalk between breast cancer stem cells and metastatic niche: Emerging molecular metastasis pathway? Tumour Biol. 34(4), 2019-2030.
62. Axelson H., Fredlund E., Ovenberger M., Landberg G., Pahlman S. 2005. Induced dedifferentiation of tumor cells: A mechanism behind heterogeneity and aggressiveness of solid tumors. Semin. Cell Dev. Biol. 16, 554-563.
63. Cannito S., Novo E., Compagnone A., Valfrè di Bonzo L., Busletta C., Zamara E., Paternostro C., Povero D., Bandino A., Bozzo F., Cravanzola C., Bravoco V., Colombatto S., Parola M. 2008. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis. 29(12), 2267-2278.
64. Alexandrova A., Kopnin P., Vasiliev J., Kopnin B. 2006. ROS up-regulation mediates Ras-induced changes of cell morphology and motility. Exp. Cell Res. 31, 2066-2073.
65. Erler J., Giaccia A. 2006. Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res. 66(21), 10238-10241.
66. Payne L., Fogelgren B., Hess R. 2006. Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res. 65, 11429-11436.
67. Fil'chenkov A. 2009. Lymphangiogenesis and tumor metstasis. Onkologiya (Kiev). 11(2), 94-103.
68. Shekhani M., Jayanthy A., Maddodi N., Seta V. 2013. Cancer stem cells and tumor transdifferentiation: Implications for novel therapeutic strategies. J. Stem Cell. 2(1), 52-61.
69. Hirschmann-Jax C., Foster A., Wulf G., Nuchtern J., Jax T., Gobel U., Goodell M., Brenner M. 2004. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. U. S. A. 101(39), 14228-14233.
70. Hirschmann-Jax C., Foster A., Wulf G., Goodell M., Brenner M. 2005. A distinct "side population" of cells in human tumor cells: Implications for tumor biology and therapy. Cell Cycle. 4(2), 203-205.
71. Palomäi S., Pietilä M., Laitinen S., Pesälä J., Sormunen R., Lehenkari P., Koivunen P. 2013. HIF-1α is upregulated in human mesenchymal stem cells. Stem Cells. 31(9), 1902-1909.
72. Abelev G. I. 1989. Alpha-fetoprotein: 25 years of study. Tumour Biol. 10(2), 63-74.